fda glp-1 compounding crackdown october 2025 The drug shortage is over. What's next for the compounders? - Pharma Technology Focus | Issue 154 FDA issued 25 warning letters

Understanding how it differs from other therapies can help you and your doctor decide if its the right fit for your personalized wellness plan

J Endocrinol (2021) 248(3):289301

PlexusDx Precision Peptide Genetic Test screens for predispositions in GIPR, GLP1R, FTO, and MC4R variants, which may help contextualize individual response patterns and support provider-led protocol refinement

It covers more pathways than CagriSema (which is missing GIP) but fewer than cag + retatrutide (which adds glucagon)

She has particular expertise in differentiating overlapping environmental and inflammatory conditions and applying structured, sequential treatment strategies to optimize patient outcomes